Compare WIA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | EDIT |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.4M | 202.1M |
| IPO Year | N/A | 2016 |
| Metric | WIA | EDIT |
|---|---|---|
| Price | $8.25 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 39.2K | ★ 1.9M |
| Earning Date | 01-01-0001 | 03-04-2026 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.56 | $0.91 |
| 52 Week High | $8.91 | $4.54 |
| Indicator | WIA | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 58.00 |
| Support Level | $8.20 | $1.92 |
| Resistance Level | $8.29 | $2.43 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 8.33 | 91.15 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.